|
|
Volumn , Issue , 2008, Pages 427-435
|
|
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANILINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
ARSENIC TRIOXIDE;
BCR ABL PROTEIN;
BOSUTINIB;
DASATINIB;
ENZYME INHIBITOR;
HARRINGTONINE DERIVATIVE;
HISTONE DEACETYLASE;
HOMOHARRINGTONINE;
IMATINIB;
NITRILE;
ORGANOARSENIC DERIVATIVE;
OXIDE;
PIPERAZINE DERIVATIVE;
PROTEIN TYROSINE KINASE;
PYRIMIDINE DERIVATIVE;
QUINOLINE DERIVATIVE;
THIAZOLE DERIVATIVE;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DRUG ANTAGONISM;
DRUG EFFECT;
DRUG RESISTANCE;
GENE AMPLIFICATION;
GENETICS;
HUMAN;
REVIEW;
ANILINE COMPOUNDS;
ANTINEOPLASTIC AGENTS;
ARSENICALS;
CLINICAL TRIALS AS TOPIC;
DRUG RESISTANCE, NEOPLASM;
ENZYME INHIBITORS;
FUSION PROTEINS, BCR-ABL;
GENE AMPLIFICATION;
HARRINGTONINES;
HISTONE DEACETYLASES;
HUMANS;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
NITRILES;
OXIDES;
PIPERAZINES;
PROTEIN-TYROSINE KINASES;
PYRIMIDINES;
QUINOLINES;
THIAZOLES;
|
|
EID: 67651162381
PISSN: 15204391
EISSN: None
Source Type: Journal
DOI: 10.1182/asheducation-2008.1.427 Document Type: Review |
|
Times cited : (53)
|
|
References (79)
|
